← Oculis Holding AG (OCS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Oculis Holding AG (OCS)
Pharmaceutical Preparations · market cap $575M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
7
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Oculis Holding AG (OCS) is a small-cap (~$1.78B market cap, 49 employees) ophthalmic-focused pharmaceutical company with a broad pipeline centered on dexamethasone-based nanoparticle formulations (OCS-01) and two late-stage non-OCS-01 assets: licaminlimab (Phase 3, Dry Eye Disease) and Privosegtor (Phase 3, Optic Neuritis). The company's most immediate high-impact catalyst is a Phase 3 readout for licaminlimab in Dry Eye Disease expected around December 15, 2026, rated 9/10 importance.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · licaminlimabimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OCS-01 | Phase 3 | Inflammation Eye Pain |
| OCS-05 +SoC (corticosteroid) IV administration | Phase 2 | Optic Neuritis |
| Dexamethasone ophthalmic suspension (OCS-01) | Phase 3 | Diabetic Macular Edema |
| Dexamethasone nanoparticles eye drops | Phase 2 | Diabetic Macular Edema |
| OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL | Phase 2 | Inflammation Corneal |
| licaminlimab | Phase 3 | Dry Eye Disease |
| Privosegtor | Phase 3 | Optic Neuritis |
Price & technical context
3-month
-38.0%
6-month
-67.6%
12-month
-50.2%
52-wk range
$8.76–$32.65
vs 50-day MA
-23.9%
vs 200-day MA
-56.6%
Realized vol
73.0%
Max drawdown
-73.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OCS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.